IL17A and psoriatic arthritis: Netakimab is an anti-IL-17A monoclonal antibody recommended for treatment of moderate-to-severe plaque psoriasis [22], ankylosing spondylitis [23] (ClinicalTrials.gov: NCT03447704) and psoriatic arthritis [24] (ClinicalTrials.gov: NCT03598751).